Equities Analysts Issue Forecasts for RNTX Q1 Earnings

Rein Therapeutics Inc. (NASDAQ:RNTX) – Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Rein Therapeutics in a research report issued to clients and investors on Thursday, April 2nd. HC Wainwright analyst B. Folkes anticipates that the company will post earnings of ($0.49) per share for the quarter. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Rein Therapeutics’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS and FY2030 earnings at $0.43 EPS.

Other analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rein Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen cut Rein Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. Citigroup downgraded Rein Therapeutics to a “hold” rating in a report on Wednesday, January 21st. Finally, lowered Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Price Performance

Shares of RNTX stock opened at $1.21 on Friday. The firm has a 50 day moving average of $1.25 and a two-hundred day moving average of $1.30. The stock has a market capitalization of $33.93 million, a PE ratio of -0.62 and a beta of 1.40. Rein Therapeutics has a 52 week low of $1.02 and a 52 week high of $2.40.

Rein Therapeutics (NASDAQ:RNTX) last announced its earnings results on Thursday, March 26th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.12).

Institutional Investors Weigh In On Rein Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Gleason Group Inc. purchased a new stake in shares of Rein Therapeutics during the 3rd quarter worth $26,000. Susquehanna International Group LLP purchased a new position in Rein Therapeutics in the third quarter valued at $35,000. HRT Financial LP acquired a new stake in Rein Therapeutics in the fourth quarter valued at $38,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Rein Therapeutics in the second quarter valued at $68,000. Finally, Jane Street Group LLC purchased a new stake in Rein Therapeutics during the 4th quarter worth about $72,000. 90.89% of the stock is currently owned by institutional investors and hedge funds.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.